How Does GvHD Typically Present?
Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.
Overview of Graft-vs-Host Disease (GvHD)
Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.
Unmet Needs and Future Perspectives in Multiple Myeloma Care
The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
Does Belantamab Have a Place in Multiple Myeloma Treatment?
The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
Preventing Infection in Patients with Multiple Myeloma During Treatment
Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma
Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
Targets in Multiple Myeloma: FcRH5
Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
Targets in Multiple Myeloma: GPRC5D
Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.
Data Updates on Immunotherapy Combinations in Multiple Myeloma
Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
Retreatment with a BCMA-Targeting Bispecific for R/R MM
Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.
CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.
Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.
Quadruplet Combination Therapies in Relapsed Multiple Myeloma
Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.
Strategies for Treatment of Multiple Myeloma at Late Relapse
The panel debates the options for treatment of late relapsed multiple myeloma.
Data Updates in the Treatment of Relapsed Multiple Myeloma
Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.
Relapse in Multiple Myeloma: Biochemical and Chemical
Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.
Defining Frailty in Multiple Myeloma for Optimal Treatment
Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.
Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.
Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512